[go: up one dir, main page]

MX2013002488A - Métodos y composiciones para suministrar un antagonista del receptor interleucina-1. - Google Patents

Métodos y composiciones para suministrar un antagonista del receptor interleucina-1.

Info

Publication number
MX2013002488A
MX2013002488A MX2013002488A MX2013002488A MX2013002488A MX 2013002488 A MX2013002488 A MX 2013002488A MX 2013002488 A MX2013002488 A MX 2013002488A MX 2013002488 A MX2013002488 A MX 2013002488A MX 2013002488 A MX2013002488 A MX 2013002488A
Authority
MX
Mexico
Prior art keywords
receptor antagonist
interleukin
methods
compositions
inflammation
Prior art date
Application number
MX2013002488A
Other languages
English (en)
Inventor
Joel Higgins
Jacy Hoeppner
Jennifer Woodell-May
Original Assignee
Biomet Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomet Biologics Llc filed Critical Biomet Biologics Llc
Publication of MX2013002488A publication Critical patent/MX2013002488A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan métodos, sistemas y composiciones relacionados con la generación y utilización de una solución rica en un antagonista del receptor de interlucina-1. Los métodos incluyen poner en contacto un líquido que comprende glóbulos blancos con un material para extracción de sólidos y la estimulación con un campo electromagnético para activar la producción del antagonista del receptor de interlucina-1. El antagonista del receptor de interlucina-1 se puede separar del material para extracción de sólidos. Los métodos para tratar un sitio de inflamación en un paciente incluyen administrar la solución rica en el antagonista del receptor de interlucina-1 al sitio de inflamación.
MX2013002488A 2010-09-03 2011-08-24 Métodos y composiciones para suministrar un antagonista del receptor interleucina-1. MX2013002488A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38002610P 2010-09-03 2010-09-03
PCT/US2011/048909 WO2012030593A2 (en) 2010-09-03 2011-08-24 Methods and compositions for delivering interleukin-1 receptor antagonist

Publications (1)

Publication Number Publication Date
MX2013002488A true MX2013002488A (es) 2013-06-03

Family

ID=44584662

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002488A MX2013002488A (es) 2010-09-03 2011-08-24 Métodos y composiciones para suministrar un antagonista del receptor interleucina-1.

Country Status (9)

Country Link
US (2) US9119829B2 (es)
EP (2) EP2977054A1 (es)
JP (1) JP2013536841A (es)
KR (1) KR20140003398A (es)
CN (1) CN103249425A (es)
AU (1) AU2011296356B2 (es)
CA (1) CA2810202C (es)
MX (1) MX2013002488A (es)
WO (1) WO2012030593A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7832566B2 (en) 2002-05-24 2010-11-16 Biomet Biologics, Llc Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
US20060278588A1 (en) 2002-05-24 2006-12-14 Woodell-May Jennifer E Apparatus and method for separating and concentrating fluids containing multiple components
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
WO2009108890A1 (en) 2008-02-27 2009-09-03 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
CN102573790B (zh) 2009-08-27 2017-03-22 拜欧米特生物制剂有限责任公司 用于产生白介素‑1受体拮抗剂的可植入装置
CN103249425A (zh) 2010-09-03 2013-08-14 巴奥米特生物公司 用于递送白介素-1受体拮抗剂的方法和组合物
CA2825551A1 (en) * 2011-01-24 2012-08-02 Progenicare, Llc Compositions and methods for promoting tissue regeneration
US9011846B2 (en) 2011-05-02 2015-04-21 Biomet Biologics, Llc Thrombin isolated from blood and blood fractions
WO2013114359A1 (en) * 2012-01-31 2013-08-08 Estar Technologies Ltd System and method for producing interleukin receptor antagonist (ira)
FR2987746B1 (fr) * 2012-03-08 2015-04-10 Adip Sculpt Seringue pour application medicale
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9950035B2 (en) * 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10208095B2 (en) * 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en) * 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
EP3074507B1 (en) 2013-11-26 2022-01-05 Biomet Biologics, LLC Methods of mediating macrophage phenotypes
EP3161479B1 (en) * 2014-06-30 2019-09-04 Biomet Biologics, LLC Methods for assessing the efficacy of anti-inflammatory cytokine compositions
CA2866480A1 (en) 2014-09-30 2016-03-30 Antnor Limited Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
CN105107233B (zh) * 2015-07-24 2017-09-22 上海市第六人民医院 去白细胞富血小板血浆的制备方法及装置
CA3013659C (en) 2016-03-10 2023-11-14 Arthrex, Inc. Systems and methods for preparing protein enhanced serums
AU2017230806B2 (en) 2016-03-10 2021-06-24 Arthrex, Inc. Systems and methods for preparing a thrombin serum
US10806942B2 (en) 2016-11-10 2020-10-20 Qoravita LLC System and method for applying a low frequency magnetic field to biological tissues
AU2020267399A1 (en) 2019-05-06 2021-12-02 Kamran Ansari Therapeutic arrays of planar coils configured to generate pulsed electromagnetic fields and integrated into clothing
US11020603B2 (en) 2019-05-06 2021-06-01 Kamran Ansari Systems and methods of modulating electrical impulses in an animal brain using arrays of planar coils configured to generate pulsed electromagnetic fields and integrated into clothing
CN111000983A (zh) * 2019-12-25 2020-04-14 长春生物制品研究所有限责任公司 一种新的重组人白细胞介素-1受体拮抗剂的药用用途
JP7025070B1 (ja) 2021-05-14 2022-02-24 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法
CN113325185B (zh) * 2021-07-09 2024-04-19 重庆鼎润医疗器械有限责任公司 多水平质控品及其制备方法和在血栓弹力图检测上的应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165938A (en) 1984-11-29 1992-11-24 Regents Of The University Of Minnesota Wound healing agents derived from platelets
SE448323B (sv) 1985-08-27 1987-02-09 Ersson Nils Olof Forfarande och anordnig att separera serum eller plasma fran blod
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5599558A (en) 1989-09-15 1997-02-04 Curative Technologies, Inc. Selecting amounts of platelet releasate for efficacious treatment of tissue
IL95641A0 (en) 1989-09-15 1991-06-30 Curative Tech Inc Preparation of a platelet releasate product
US5641622A (en) 1990-09-13 1997-06-24 Baxter International Inc. Continuous centrifugation process for the separation of biological components from heterogeneous cell populations
GB9307321D0 (en) 1993-04-07 1993-06-02 Knight Scient Ltd Method of separating particles from a filter
US5571418A (en) 1993-08-20 1996-11-05 Lee; Patrice A. Hemofiltration of toxic mediator-related disease
US5585007A (en) 1994-12-07 1996-12-17 Plasmaseal Corporation Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant
AU5309396A (en) 1995-04-13 1996-10-30 Travenol Laboratories (Israel) Ltd. Leukocyte filtration method and apparatus
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
JPH1045616A (ja) 1996-08-02 1998-02-17 Shionogi & Co Ltd 注射用徐放性製剤
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
JP4038331B2 (ja) 1997-08-16 2008-01-23 オルソゲン アーゲー 治療効果を有するタンパク質を誘導するための方法
CA2335811C (en) 1998-06-23 2006-01-31 Shanbrom Technologies, Llc Method and apparatus for the production of purified plasma proteins
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
DE19903876B4 (de) 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten
US6398972B1 (en) 1999-04-12 2002-06-04 Harvest Technologies Corporation Method for producing platelet rich plasma and/or platelet concentrate
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US20030091536A1 (en) 1999-09-07 2003-05-15 Colorado State University Research Foundation In vivo treatment of joint disease using interleukin-1
US6645388B2 (en) 1999-12-22 2003-11-11 Kimberly-Clark Corporation Leukocyte depletion filter media, filter produced therefrom, method of making same and method of using same
US8017369B2 (en) 2000-02-23 2011-09-13 The Trustees Of The University Of Pennsylvania System and method of up-regulating bone morphogenetic proteins (BMP) gene expression in bone cells via the application of fields generated by specific and selective electric and electromagnetic signals
EP2241328A1 (en) 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
DK1294414T3 (da) 2000-06-29 2006-07-24 Biosyntech Canada Inc Præparat og fremgangsmåde til heling og regenerering af brusk og andre væv
US6790371B2 (en) 2001-04-09 2004-09-14 Medtronic, Inc. System and method for automated separation of blood components
US7011852B2 (en) 2001-05-07 2006-03-14 Hemogenesis, Llc Separation of platelets from whole blood for use as a healant
US6649072B2 (en) 2001-11-16 2003-11-18 Robert Brandt Method for producing autologous platelet-rich plasma
US7608258B2 (en) 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US6811777B2 (en) 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US20030198687A1 (en) 2002-04-18 2003-10-23 Keith Bennett, M.D. Wound care composition
US20040182795A1 (en) 2003-03-21 2004-09-23 Randel Dorian Apparatus and method for concentration of plasma from whole blood
US7832566B2 (en) 2002-05-24 2010-11-16 Biomet Biologics, Llc Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
US7179391B2 (en) 2002-05-24 2007-02-20 Biomet Manufacturing Corp. Apparatus and method for separating and concentrating fluids containing multiple components
US7992725B2 (en) 2002-05-03 2011-08-09 Biomet Biologics, Llc Buoy suspension fractionation system
US6905612B2 (en) 2003-03-21 2005-06-14 Hanuman Llc Plasma concentrate apparatus and method
US7374678B2 (en) 2002-05-24 2008-05-20 Biomet Biologics, Inc. Apparatus and method for separating and concentrating fluids containing multiple components
US20030205538A1 (en) 2002-05-03 2003-11-06 Randel Dorian Methods and apparatus for isolating platelets from blood
US20060278588A1 (en) 2002-05-24 2006-12-14 Woodell-May Jennifer E Apparatus and method for separating and concentrating fluids containing multiple components
WO2004009207A1 (en) 2002-07-18 2004-01-29 Hanuman Llc Plasma concentrating apparatus and method
WO2004011631A2 (en) 2002-07-26 2004-02-05 Ebi, L.P. Methods and compositions for treating tissue defects using pulsed electromagnetic field stimulus
US6955642B1 (en) 2002-11-26 2005-10-18 Ebi, Lp Pulsed electromagnetic field stimulation method and apparatus with improved dosing
US20040120942A1 (en) 2002-12-23 2004-06-24 Mcginnis Daniel Device and process for the preparation of autologous thrombin serum
US20050059153A1 (en) * 2003-01-22 2005-03-17 George Frank R. Electromagnetic activation of gene expression and cell growth
US20050049640A1 (en) 2003-05-12 2005-03-03 Gurtner Geoffrey C. Electromagnetic fields increase in vitro and in vivo angiogenesis through endothelial release of FGF-2
JP4965251B2 (ja) 2003-07-09 2012-07-04 ウォーソー・オーソペディック・インコーポレーテッド 結合組織成長コンポーネントが豊富に含まれる骨髄画分の単離、及び結合組織の形成を促進するためのその使用
US20050084962A1 (en) 2003-08-20 2005-04-21 Bruce Simon Methods of treatment using electromagnetic field stimulated stem cells
US7744869B2 (en) * 2003-08-20 2010-06-29 Ebi, Llc Methods of treatment using electromagnetic field stimulated mesenchymal stem cells
AU2004281080A1 (en) 2003-10-16 2005-04-28 Stephen John Ralph Immunomodulating compositions and uses therefor
CN1980696B (zh) 2004-04-30 2012-09-26 血液分离生物技术有限公司 除去病人体内可溶性tnfr1，tnfr2和il2的方法和系统
US20060051865A1 (en) 2004-08-31 2006-03-09 Higgins Joel C Systems and methods for isolating stromal cells from adipose tissue and uses thereof
US20060057223A1 (en) 2004-09-10 2006-03-16 Dimauro Thomas M Intradiscal production of autologous interleukin antagonist
US7520849B1 (en) 2004-09-20 2009-04-21 Ebi, Lp Pulsed electromagnetic field method of treating soft tissue wounds
EP2666494B1 (en) 2005-02-07 2018-01-17 Hanuman LLC Platelet rich plasma concentrate apparatus and method
WO2006086201A2 (en) 2005-02-07 2006-08-17 Hanuman Llc Platelet rich plasma concentrate apparatus and method
EP1848473B1 (en) 2005-02-07 2013-05-22 Hanuman LLC Plasma concentrator device
US7866485B2 (en) 2005-02-07 2011-01-11 Hanuman, Llc Apparatus and method for preparing platelet rich plasma and concentrates thereof
US7694828B2 (en) 2005-04-27 2010-04-13 Biomet Manufacturing Corp. Method and apparatus for producing autologous clotting components
US8048297B2 (en) 2005-08-23 2011-11-01 Biomet Biologics, Llc Method and apparatus for collecting biological materials
US7771590B2 (en) 2005-08-23 2010-08-10 Biomet Manufacturing Corp. Method and apparatus for collecting biological materials
US20070105769A1 (en) 2005-11-07 2007-05-10 Ebi, L.P. Methods of treating tissue defects
DE102006005016A1 (de) 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung
GB0607189D0 (en) 2006-04-10 2006-05-17 Polybiomed Ltd interleukin IL 1ra composition
WO2007127834A2 (en) 2006-04-26 2007-11-08 Medtronic, Inc. Compositions and methods of preparation thereof
WO2007121538A1 (en) 2006-04-26 2007-11-01 Plasma Ventures Pty Ltd Anti-inflammatory blood product and method of use
US9598673B2 (en) 2006-05-19 2017-03-21 Creative Medical Health Treatment of disc degenerative disease
WO2008022651A1 (en) 2006-08-21 2008-02-28 Antoine Turzi Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells
US20080064626A1 (en) 2006-09-08 2008-03-13 Zanella John M Methods of treating tendonitis in a subject by using an anti-cytokine agent
WO2008069975A2 (en) 2006-12-01 2008-06-12 New York University Methods of using f-spondin as a biomarker for cartilage degenerative conditions
US20080193424A1 (en) 2007-02-09 2008-08-14 Biomet Biologics, Inc. Treatment of tissue defects with a therapeutic composition
US8034014B2 (en) * 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
EP2146794B1 (en) 2007-04-12 2016-10-19 Biomet Biologics, LLC Buoy suspension fractionation system
US20080269762A1 (en) 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
US20080268064A1 (en) 2007-04-25 2008-10-30 Biomet Biologics, Inc. Method for treating cartilage defects
US7901344B2 (en) 2007-05-11 2011-03-08 Biomet Biologics, Llc Methods of reducing surgical complications in cancer patients
WO2008157733A2 (en) 2007-06-19 2008-12-24 Baxter International Inc. Fibrin gel for controlled release of pdgf and uses thereof
US8672869B2 (en) 2007-10-30 2014-03-18 Bellco S.R.L. Kit, system and method of treating myeloma patients
CN101945891A (zh) 2007-12-20 2011-01-12 爱克索马技术有限公司 治疗痛风的方法
US20090192528A1 (en) 2008-01-29 2009-07-30 Biomet Biologics, Inc. Method and device for hernia repair
WO2009108890A1 (en) 2008-02-27 2009-09-03 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US8337711B2 (en) 2008-02-29 2012-12-25 Biomet Biologics, Llc System and process for separating a material
ES2610327T3 (es) 2008-03-13 2017-04-27 Biotest Ag Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
AU2009235622C9 (en) 2008-03-13 2015-07-02 Biotest Ag Agent for treating disease
RU2539110C2 (ru) 2008-03-13 2015-01-10 Биотест Аг Способ лечения аутоиммунного заболевания (варианты)
US8182769B2 (en) 2008-04-04 2012-05-22 Biomet Biologics, Llc Clean transportation system
US8518272B2 (en) 2008-04-04 2013-08-27 Biomet Biologics, Llc Sterile blood separating system
EP2293816B1 (en) 2008-06-06 2012-11-07 XOMA Technology Ltd. Methods for the treatment of rheumatoid arthritis
WO2009152084A2 (en) 2008-06-11 2009-12-17 Cell4Vet Llc Adipose tissue-derived stem cells for veterinary use
US8460227B2 (en) 2008-11-17 2013-06-11 Arthrex, Inc. Cytokine concentration system
US8177072B2 (en) 2008-12-04 2012-05-15 Thermogenesis Corp. Apparatus and method for separating and isolating components of a biological fluid
US20120093936A1 (en) 2009-04-07 2012-04-19 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
WO2010149164A2 (en) * 2009-06-22 2010-12-29 Re5 Aps Apparatus and method for pulsed electrical field treatment
US20110052561A1 (en) 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
CN102573790B (zh) 2009-08-27 2017-03-22 拜欧米特生物制剂有限责任公司 用于产生白介素‑1受体拮抗剂的可植入装置
US20120027746A1 (en) 2010-07-30 2012-02-02 Biomet Biologics, Llc Method for generating thrombin
CN103249425A (zh) 2010-09-03 2013-08-14 巴奥米特生物公司 用于递送白介素-1受体拮抗剂的方法和组合物

Also Published As

Publication number Publication date
WO2012030593A2 (en) 2012-03-08
US20160000870A1 (en) 2016-01-07
EP2977054A1 (en) 2016-01-27
CA2810202A1 (en) 2012-03-08
KR20140003398A (ko) 2014-01-09
AU2011296356B2 (en) 2015-07-09
US9119829B2 (en) 2015-09-01
WO2012030593A3 (en) 2012-05-18
JP2013536841A (ja) 2013-09-26
AU2011296356A1 (en) 2013-03-21
EP2611456A2 (en) 2013-07-10
CA2810202C (en) 2018-02-20
US20130178425A1 (en) 2013-07-11
CN103249425A (zh) 2013-08-14

Similar Documents

Publication Publication Date Title
MX2013002488A (es) Métodos y composiciones para suministrar un antagonista del receptor interleucina-1.
WO2011031524A3 (en) Methods and compositions for delivering interleukin-1 receptor antagonist
IL221373A0 (en) System for determining treatment-related data for the administration of drugs to patients to be treated for the administration of drugs to patients to be treated taking into account important individual factors
NZ609201A (en) Means and methods for treating dlbcl
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
WO2014108571A3 (en) Cancer drug and uses
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
IN2012DN06720A (es)
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
MX366336B (es) Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
IN2014KN00996A (es)
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
SG10201902353UA (en) Capturing specific nucleic acid materials from individual biological cells in a micro-fluidic device
UA111738C2 (uk) Спосіб активної клітинної імунотерапії раку шляхом застосування пухлинних клітин, знищених за допомогою високого гідростатичного тиску, і дендритних клітин
MY175332A (en) Methods of administering beta7 integrin antagonists
SG10201803778PA (en) Treatment for rheumatoid arthritis
IN2014DN08598A (es)
EA201491258A1 (ru) Самосшивающие катетеры
WO2013090523A3 (en) Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
MX390695B (es) Composiciones farmaceuticas solidas antidiabeticas
GB2534478A (en) Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo
WO2012009640A3 (en) B cell depletion for central nervous system injuries and methods and uses thereof
MX359106B (es) Composicion farmaceutica inyectable de dexketoprofeno y tramadol.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal